Medication Monitor

Generic Name (Trade Name—Company)
November 30, 2011

Levonorgestrel and ethinyl estradiol

(Myzilra—Qualitest, Endo)
New triphasic contraceptive


Prevention of pregnancy

A new oral contraceptive containing levonorgestrel and ethinyl estradiol has been approved by FDA, according to a news release from Qualitest Pharmaceuticals and Endo. This new product provides a 28-day triphasic regimen that contains levonorgestrel and ethinyl estradiol tablets in three dosage-strength combinations: 0.05 mg/0.03 mg, 0.075 mg/0.04 mg, 0.125 mg/0.03 mg.